Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching | Zendy

Tao Li | Zendy; Yundong Qu | Zendy; Yan Wang | Zendy; Chunlei Lin | Zendy; Baohua Yang | Zendy; Lei Wang | Zendy

Open Access

Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching

Author(s) -

Tao Li,

Yundong Qu,

Yan Wang,

Chunlei Lin,

Baohua Yang,

Lei Wang

Publication year - 2019

Publication title -

journal of college of physicians and surgeons pakistan

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.229

H-Index - 33

eISSN - 1681-7168

pISSN - 1022-386X

DOI - 10.29271/jcpsp.2019.04.317

Subject(s) - entecavir , propensity score matching , medicine , hepatocellular carcinoma , gastroenterology , hepatology , cirrhosis , incidence (geometry) , proportional hazards model , cohort , hepatitis b virus , virology , virus , lamivudine , physics , optics

To compare the reduction of hepatocellular carcinoma (HCC) risk between long-term treatment of entecavir and low genetic barrier antiviral agents in hepatitis B virus (HBV)-related cirrhotic patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research